July 13, 2023 03:44 PM EDT

CMS proposes coverage for pre-exposure prophylaxis regimens to prevent HIV

Nicole DeFeudis

Editor

The Centers for Medicare and Medicaid Services on Wednesday proposed coverage for pre-exposure prophylaxis (PrEP) using antiretroviral therapy to prevent HIV infections.

The news comes nearly six months after CMS initiated a national coverage analysis for PrEP. Medicare coverage for PrEP currently varies by plan, though many patients are left with high out-of-pocket costs. According to one 2020 study that analyzed a variety of Medicare plans in the Ann Arbor, MI area, the average annual cost for someone with a prescription drug plan was between $2,276 and $2,430, including deductibles, monthly premiums, copays and coinsurance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

CMS proposes coverage for pre-exposure prophylaxis regimens to prevent HIV

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

‘A new era of growth’: AstraZeneca aims for $80B revenue, 20 new drugs by 2030

Exclusive: Members of Congress buy and sell stocks that would gain from bill banning China biotech companies

Dyne Therapeutics sharpens case for two muscle disease therapies with updated data

FDA approves first two interchangeable biosimilars to Regeneron's blockbuster Eylea

FDA withdraws Helsinn’s accelerated approval for cancer drug after company’s request

Back to the future: From target-selective drug design to AI-enabled polypharmacology

CMS pro­pos­es cov­er­age for pre-ex­po­sure pro­phy­lax­is reg­i­mens to pre­vent HIV

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

‘A new era of growth’: As­traZeneca aims for $80B rev­enue, 20 new drugs by 2030

Ex­clu­sive: Mem­bers of Con­gress buy and sell stocks that would gain from bill ban­ning Chi­na biotech com­pa­nies

Dyne Ther­a­peu­tics sharp­ens case for two mus­cle dis­ease ther­a­pies with up­dat­ed da­ta

FDA ap­proves first two in­ter­change­able biosim­i­lars to Re­gen­eron's block­buster Eylea

FDA with­draws Helsinn’s ac­cel­er­at­ed ap­proval for can­cer drug af­ter com­pa­ny’s re­quest

Back to the fu­ture: From tar­get-se­lec­tive drug de­sign to AI-en­abled polyphar­ma­col­o­gy

CMS proposes coverage for pre-exposure prophylaxis regimens to prevent HIV

‘A new era of growth’: AstraZeneca aims for $80B revenue, 20 new drugs by 2030

Exclusive: Members of Congress buy and sell stocks that would gain from bill banning China biotech companies

Dyne Therapeutics sharpens case for two muscle disease therapies with updated data

FDA approves first two interchangeable biosimilars to Regeneron's blockbuster Eylea

FDA withdraws Helsinn’s accelerated approval for cancer drug after company’s request

Back to the future: From target-selective drug design to AI-enabled polypharmacology